Manufacturer of Controlled Substances; Notice of Registration, 58313 [E9-27194]
Download as PDF
<![CDATA[
58313
Federal Register / Vol. 74, No. 217 / Thursday, November 12, 2009 / Notices
reaching the decision to lease and
subsequently convey under the R&PP
Act, or any other factor not directly
related to the suitability of the land for
R&PP use. Any adverse comments will
be reviewed by the BLM Nevada State
Director, who may sustain, vacate, or
modify this realty action. In the absence
of any adverse comments, this realty
action will become the final
determination of the Department of the
Interior.
Before including your address, phone
number, e-mail address, or other
personal identifying information in your
comment, you should be aware that
your entire comment—including your
personal identifying information—may
be made publicly available at any time.
While you may ask us in your comment
to withhold your personal identifying
information from public review, we
cannot guarantee that we will be able to
do so. Only written comments
submitted by postal service or overnight
mail to the Field Manager, BLM Las
Vegas Field Office, will be considered
properly filed. Electronic mail,
facsimile, or telephone comments will
not be considered properly filed.
In the absence of any adverse
comments, the decision will become
effective January 11, 2010. The lands
will not be available for lease or
subsequent conveyance until after the
decision becomes effective.
(Authority: 43 CFR 2741.5)
Kimber Liebhauser,
Assistant Field Manager, Division of Lands.
[FR Doc. E9–27089 Filed 11–10–09; 8:45 am]
Drug
Schedule
Methadone Intermediate (9254) ...
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for formulation
into finished pharmaceuticals.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Boehringer Ingelheim Chemicals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Boehringer Ingelheim
Chemicals, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 USC § 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–27194 Filed 11–10–09; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4310–HC–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
Drug Enforcement Administration
jlentini on DSKJ8SOYB1PROD with NOTICES
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated June 15, 2009, and
published in the Federal Register on
June 23, 2009, (74 FR 29719),
Boehringer Ingelheim Chemicals, Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedule II:
Drug
Schedule
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Methadone (9250) ........................
VerDate Nov<24>2008
16:12 Nov 10, 2009
II
II
II
II
Jkt 220001
By Notice dated June 15, 2009, and
published in the Federal Register on
June 23, 2009, (74 FR 29719), Noramco
Inc., Division of Ortho-McNeil, Inc.,
1440 Olympic Drive, Athens, Georgia
30601, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Tapentadol (9780), a
basic class of controlled substance listed
in schedule II.
The company plans to bulk
manufacture the above listed controlled
substance for distribution to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Noramco, Inc. to manufacture the listed
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated
Noramco, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. § 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–27180 Filed 11–10–09; 8:45 am]
BILLING CODE 4410–09–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated April 17, 2009, and
published in the Federal Register on
April 29, 2009, (74 FR 19599), Stepan
Company, Natural Products Dept., 100
W. Hunter Avenue, Maywood, New
Jersey 07607, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedule II:
Drug
Cocaine (9041) .............................
Benzoylecgonine (9180) ...............
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Stepan Company to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Stepan Company to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
E:\FR\FM\12NON1.SGM
12NON1
]]>Agencies
[Federal Register Volume 74, Number 217 (Thursday, November 12, 2009)]
[Notices]
[Page 58313]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-27194]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated June 15, 2009, and published in the Federal
Register on June 23, 2009, (74 FR 29719), Boehringer Ingelheim
Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as a bulk manufacturer of the basic classes of
controlled substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Methadone (9250)........................... II
Methadone Intermediate (9254).............. II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers for formulation into finished
pharmaceuticals.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Boehringer Ingelheim Chemicals, Inc. to manufacture the listed basic
classes of controlled substances is consistent with the public interest
at this time. DEA has investigated Boehringer Ingelheim Chemicals, Inc.
to ensure that the company's registration is consistent with the public
interest. The investigation has included inspection and testing of the
company's physical security systems, verification of the company's
compliance with state and local laws, and a review of the company's
background and history. Therefore, pursuant to 21 USC Sec. 823, and in
accordance with 21 CFR 1301.33, the above named company is granted
registration as a bulk manufacturer of the basic classes of controlled
substances listed.
Dated: November 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-27194 Filed 11-10-09; 8:45 am]
BILLING CODE 4410-09-P
